Skanditek's portfolio company Vitrolife completes a private share issue

Skanditek's portfolio company Vitrolife completes a private share issue Vitrolife AB (publ), which is one of Skanditek's portfolio companies, has completed a directed private share issue to institutional investors with the purpose of strengthening the capital base before forthcoming invest- ments. We refer to enclosed press release from Vitrolife. Skanditek's holding in Vitrolife is unchanged and amounts to 1,379,877 Class A shares and 5,115,823 Class B shares, which gives a total of 6,495,700 shares. The holding represents 47.2 percent of the votes and 45.1 percent of the capital after the new issue. Stockholm, November 2, 2000 SKANDITEK INDUSTRIFÖRVALTNING AB (publ) For further information, please contact: Patrik Tigerschiöld, president, phone +46 (0)8 614 00 20, mobile +46 (0)70 777 71 90, e-mail: patrik.tigerschiold@skanditek.se. Skanditek is an industrial holding company owning long-term stock in Swed- ish unlisted and listed companies. Our business concept is to be an active stockholder and to further their development process by providing indus- trial and financial competence at board and management level. Our aim is to generate long-term capital growth for stockholders. The portfolio com- prises some twenty holdings structured in the areas electronics, informa- tion technology, biotechnology and services. The major holdings are in Axis (14 %), LGP Telecom Holding (10 %), Mydata Automation (39 %), Part- nerTech (26 %), Vellinge Electronics (100 %) and Vitrolife (48 %). Skan- ditek is listed on the OM Stockholm Exchange's O list and has a market value of about SEK 3.5 billion. Press release Gothenburg November 2, 2000 Vitrolife completes a private share issue of SEK 70 million Vitrolife, a leading provider of innovative products and systems for cell and tissue technologies, has completed a private share issue of SEK 70 million following an offering managed by Enskilda Securities. The shares were issued to institutional and other investors, including Er- nesto Bertarelli, Chief Executive of Serono AS; world leader in reproduc- tive health care. - We are very pleased to have raised this additional equity for invest- ments in manufacturing capability, IT infrastructure and R&D in order to meet the increased demand for Vitrolife's products internationally, said Peter Svalander, President and CEO of Vitrolife. Vitrolife is planning for an Initial Public Offering and listing on the OM Stockholm Exchange in the spring 2001. For further information, please contact Peter Svalander, CEO of Vitrolife +46-31-721 8001 or + 46 708 228001 e-mail: psvalander@vitrolife.com Professor Lars Hamberger, Chairman of the Board + 46 31 721 8027 or + 46 708 228027 e-mail: lhamberger@vitrolife.com Vitrolife is a leading Swedish Biotech Company within the area of develop- ment, production, and sales of complex solutions for assisted reproduc- tion, cell therapy and organ transplantation. Vitrolife's products are marketed in more than 65 countries, and the company is a world leader in the area of in vitro fertilisation (IVF). For further information, please see: www.vitrolife.com ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/11/02/20001102BIT00850/bit0001.doc http://www.bit.se/bitonline/2000/11/02/20001102BIT00850/bit0002.pdf